WILMINGTON, Del. and HAIFA, Israel, Sept 7, 2016 /PRNewswire/ — NeuroRx, a clinical-stage pharmaceutical company developing CycluradTM, a first-in-class, potentially breakthrough drug for the prevention of suicide in bipolar depression, announced today that it will be featured as a presenting company at the 18th Annual Rodman & Renshaw Global Investment Conference, sponsored by H.C. Wainwright & Co., LLC. The conference is being held on September 11-13, 2016, at the Lotte New York Palace Hotel in New York City.
NeuroRx CEO and co-founder Jonathan Javitt M.D., MPH will provide an overview of the Company’s business during the live presentation and will be available to participate in one-on-one meetings with investors who are registered to attend the conference.
If you are an institutional investor, and would like to attend the Company’s presentation, please click on the following link (www.rodmanevents.com) to register for conference. Once your registration is confirmed, you will be prompted to log into the conference website to request a one-on-one meeting with the Company.
Event: 18th Annual Rodman & Renshaw Global Investment
Date: Monday, September 12
Time: 3:00-3:25 PM
Presenters: Jonathan C. Javitt, MD, MPH
Location: Roswell (4th Floor)
“People with bipolar depression can be 20-30 times more likely to attempt suicide than the general population,” Javitt says. “In an acute suicidal crisis, they need help urgently. Today there is no approved medicine to treat this disease state. In fact, patients with a risk of suicide have been excluded from clinical registration studies.”
Javitt will discuss the company’s in-development drug, CycluradTM, the first oral therapeutic for the treatment of Acute/Elevated Suicidal Ideation/Crisis in Bipolar Depression (ASIBD/ESIBD). Earlier this year NeuroRx had a pre-IND meeting with the FDA, which confirmed its development path through a 505(b)(2) approach and its potential for breakthrough designation. Attendees will also hear about the realities of bipolar disorder and suicide.
- About 5.7 million Americans age 18 and older have bipolar disorder, and 30%-50% of them will have depressive episodes this year.,
- Of the 40,000+ suicides in the U.S. each year, 20%-60% may be related to bipolar depression.
CycluradTM Treatment is a potential rapid-onset 6-week regimen for acute or elevated suicidal ideation/crisis associated with bipolar depression. The treatment, which is currently in research phase, is a proprietary, oral, fixed-dose combination of two FDA-approved drugs: D-cycloserine, a N-methyl-D-aspartate (NMDA) receptor modulator; and lurasidone, a 5-HT2a receptor antagonist. NeuroRx’s investigational treatment approach begins with a single dose of intravenous ketamine, an FDA approved anesthetic for surgeries (not currently approved for depression or suicidal ideation). Ketamine, a controlled substance with potential for abuse, has shown a rapid antidepressant/anti-suicidal effect, though it lasts only a few days, and must be administered in a clinic-like setting as it can lead to hallucinations and cardiovascular side effects. This one-time induction is then followed by six weeks of daily oral CycluradTM. Findings from two Phase II clinical studies have been published in peer-reviewed journals, showing a 50% reduction in symptoms of depression and a 75% reduction in suicidal ideation in bipolar patients.
About NeuroRx, Inc.
NeuroRx, Inc., is a privately funded, clinical stage pharmaceutical company that is developing CycluradTM, as the first oral therapeutic for the treatment of Acute/Elevated Suicidal Ideation/crisis associated with Bipolar Depression (ASIBD/ESIBD). The company is built upon 30 years of basic science and clinical expertise in understanding the role of the brain’s N-methyl-D-aspartate (NMDA) receptor in regulating human thought processes in general, and more specifically in regulating depression and suicidality. NeuroRx expects to initiate a Phase II/III clinical trial of CycluradTM in late 2016.